This inventor holds 3 USPTO granted patents and 2 published patent applications. Top assignee: Microbiotica Gmbh. Active years: 2022-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2022-2026
Title: Simon Harris: Innovator in Cancer Treatment
Introduction
Simon Harris is a notable inventor based in Cambridge, GB. He has made significant contributions to the field of cancer treatment through his innovative research and patented inventions. With a total of 3 patents, Harris is dedicated to advancing medical science and improving patient outcomes.
Latest Patents
Harris's latest patents include a therapeutic bacterial composition and a bacterial biomarker. The therapeutic bacterial composition relates to bacterial compositions that are useful in the treatment of cancer. In particular, these compositions can be utilized as a co-therapy with immune checkpoint therapy. Additionally, the invention encompasses methods for identifying subjects who will respond to therapy with an immune checkpoint inhibitor by determining the abundance of bacteria in a biological sample from the subject. The bacterial biomarker patent shares similar applications, emphasizing the importance of bacterial compositions in cancer treatment.
Career Highlights
Simon Harris works at Microbiotica GmbH, where he continues to explore innovative solutions for cancer therapy. His work is characterized by a commitment to research and development in the field of microbiome science and its applications in oncology.
Collaborations
Harris collaborates with esteemed colleagues, including Matthew Robinson and Trevor Lawley. Their combined expertise contributes to the advancement of research in therapeutic applications of bacterial compositions.
Conclusion
In summary, Simon Harris is a pioneering inventor whose work in cancer treatment through bacterial compositions is making a significant impact in the medical field. His patents reflect a commitment to innovation and improving therapeutic strategies for patients.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile